The dual metformin and GLP‐1 RA treatment arm was younger, more likely to be of white ethnicity, and have a higher BMI, HbA1c, and eGFR, but less likely to have CVD, hypertension, or dyslipidaemia, compared with the DPP4i arm (Table 1). This evidence concerns the gene GLP1R and Hypertension.